5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.89▼ | 2.88▲ | 2.88▲ | 2.86▲ | 2.79▲ |
MA10 | 2.88▲ | 2.88▲ | 2.86▲ | 2.84▲ | 2.77▲ |
MA20 | 2.88▲ | 2.86▲ | 2.86▲ | 2.78▲ | 2.68▲ |
MA50 | 2.87▲ | 2.86▲ | 2.85▲ | 2.75▲ | 2.33▲ |
MA100 | 2.87▲ | 2.85▲ | 2.80▲ | 2.66▲ | 2.45▲ |
MA200 | 2.86▲ | 2.80▲ | 2.82▲ | 2.32▲ | 2.89▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.001▲ | 0.002▲ | 0.003▲ | 0.009▲ | 0.002▲ |
RSI | 56.177▲ | 57.494▲ | 56.795▲ | 56.455▲ | 59.450▲ |
STOCH | 81.944▲ | 71.128 | 75.817 | 72.245 | 51.178 |
WILL %R | -25.000▲ | -11.111▲ | -11.111▲ | -21.212▲ | -40.404 |
CCI | 70.525 | 54.783 | 66.188 | 68.466 | 55.879 |
Monday, May 13, 2024 09:00 AM
WARMINSTER, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a ...
|
Saturday, May 11, 2024 08:00 AM
Jefferies raised the price target for the Arbutus Biopharma Corp (NASDAQ:ABUS) stock from “a Hold” to “a Buy”. The rating was released on February 02, 2022, according to finviz. The research report ...
|
Friday, May 10, 2024 04:00 AM
Arbutus Biopharma Corporation (Nasdaq: ABUS) will present at two investor conferences in New York next month. The biopharmaceutical company is set for a fireside chat at the ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
16/05/24 | 2.81 | 2.90 | 2.81 | 2.89 | 342,064 |
15/05/24 | 2.88 | 2.91 | 2.805 | 2.81 | 430,695 |
14/05/24 | 2.86 | 2.90 | 2.81 | 2.86 | 475,468 |
13/05/24 | 2.89 | 2.92 | 2.85 | 2.88 | 366,777 |
10/05/24 | 2.96 | 2.96 | 2.7903 | 2.88 | 697,958 |
09/05/24 | 2.86 | 2.95 | 2.79 | 2.94 | 688,712 |
08/05/24 | 2.86 | 2.865 | 2.76 | 2.84 | 503,997 |
07/05/24 | 2.81 | 2.84 | 2.79 | 2.84 | 619,185 |
06/05/24 | 2.71 | 2.82 | 2.70 | 2.80 | 685,435 |
03/05/24 | 2.71 | 2.85 | 2.70 | 2.71 | 683,613 |
|
|
||||
|
|
||||
|
|